CSB inhibitors, short for Cockayne syndrome group B protein inhibitors, belong to a class of compounds designed to target a specific cellular protein known as CSB (Cockayne syndrome group B protein). CSB is a crucial component of the transcription-coupled nucleotide excision repair (TC-NER) pathway, which is responsible for repairing DNA damage caused by various environmental factors, such as ultraviolet (UV) radiation and chemical agents. This pathway plays a vital role in maintaining genomic stability and preventing the accumulation of DNA lesions that can lead to mutations and cancer. CSB inhibitors are designed to modulate the activity of the CSB protein, and their development has garnered significant interest in the field of molecular biology and genetics.
These inhibitors typically work by disrupting the binding of CSB to DNA or interfering with its enzymatic functions involved in the repair process. By doing so, they can impair the cell's ability to repair damaged DNA, leading to an accumulation of DNA lesions and, in some cases, cell death. Researchers have been studying CSB inhibitors not only to better understand the molecular mechanisms underlying DNA repair but also to explore their applications in various fields, such as cancer research and genetic studies. Additionally, these inhibitors have provided valuable insights into the broader field of DNA repair and may contribute to the development of novel strategies for combating diseases associated with defective DNA repair pathways.